BioAmber (BIOA) inks agreements with institutional investors for the aggregate sale of 46.67M Series A units (or equivalent Series B units) at a price of $0.15 per unit ($0.149/Series B unit to pay for the pre-funded warrant), 40% below its planned public offering price of $0.25 per unit.
The company has terminated its previously announced public offering.
Shares are off 7%.
Previously: BioAmber prices equity offering (Feb. 6)
Subscribe for full text news in your inbox